Wright R A, Perrie A M, Stenhouse F, Alberti K G, Riemersma R A, MacGregor I R, Boon N A
Cardiovascular Research Unit, University of Edinburgh, UK.
Eur J Clin Pharmacol. 1994;46(3):279-82. doi: 10.1007/BF00192563.
This double-blind, randomized parallel group study investigated the effect of 6 months beta-adrenoceptor antagonist therapy with either metoprolol (beta 1-selective without intrinsic sympathomimetic activity [ISA]) or epanolol (beta 1-selective with ISA) on markers of endogenous fibrinolysis in 20 patients with chronic stable angina receiving concurrent treatment with nifedipine. Neither drug had an effect on tissue-type plasminogen activator or plasminogen activator inhibitor type 1 (PAI-1). A significant correlation between fasting insulin and PAI-1 has previously been described and was confirmed in this study. The group treated with metoprolol showed a significant rise in fasting insulin after 6 months with no change in PAI-1. This suggests that the previously described link between these two may not be causal.
这项双盲、随机平行组研究调查了在20例接受硝苯地平联合治疗的慢性稳定型心绞痛患者中,使用美托洛尔(β1选择性,无内在拟交感活性[ISA])或依泮洛尔(β1选择性,有ISA)进行6个月β肾上腺素能受体拮抗剂治疗对内源性纤维蛋白溶解标志物的影响。两种药物对组织型纤溶酶原激活物或纤溶酶原激活物抑制剂1(PAI-1)均无影响。先前已描述并在本研究中证实空腹胰岛素与PAI-1之间存在显著相关性。接受美托洛尔治疗的组在6个月后空腹胰岛素显著升高,而PAI-1无变化。这表明先前描述的这两者之间的联系可能不是因果关系。